Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Rival Abbott launched its own OTC CGM, Lingo, weeks after Dexcom's Stelo debut. The company is counting on further international expansion to drive growth after it said it had improved access to ...

SAN DIEGO, August 26, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the ...

Its innovative CGM systems, like the G6 and the newer G7 ... G7 system and further development of offerings like the Dexcom Stelo, targeting non-insulin-using diabetes patients.

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.